Novartis suspends production of two radiopharmaceutical drugs over quality concerns
Bio Pharma Dive
MAY 6, 2022
Due to potential issues in manufacturing, the pharma is halting deliveries of two cancer drugs, Lutathera and Pluvicto, in the U.S. and Canada, a setback for a business in which the company has invested heavily.
Let's personalize your content